Philadelphia-based novel gene therapy startup Passage Bio says it closed a $110 million Series B round of funding, less than seven months after raising a $115.5 million Series A. The company’s latest round of funding was led by Access Biotechnology, with participation from existing investors OrbiMed, Frazier Healthcare Partners, Versant Ventures, Lily Asia Ventures, New Leaf Venture Partners and Vivo Capital. The round also included new investors Boxer Capital of Tavistock Group, Highline Capital Management, Logos Capital and Sphera Funds Management.
Read more. (Bizjournal.com)